Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
18 nov. 2024 18h20 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new...
Telix ADSs Commence Trading on Nasdaq
13 nov. 2024 16h28 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced...
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
13 nov. 2024 03h26 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration...
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
03 nov. 2024 17h03 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare...
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
30 oct. 2024 06h33 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a partnership with California-based Subtle Medical, Inc. (Subtle...
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
23 oct. 2024 18h01 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA)...
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
22 oct. 2024 06h39 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the spin-off of Rhine Pharma1, which has the mission of expanding...
Telix Files Form 20-F Registration Statement for Nasdaq ADS
17 oct. 2024 17h28 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has publicly filed a Form 20-F registration statement...
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
17 oct. 2024 03h31 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the...
Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
04 oct. 2024 07h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Health Canada has approved the use of Illuccix® (kit for the...